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SUMMARY 
Background: Provision of early intervention services has increased the rate of social 
recovery in patients with first episode psychosis; however, many individuals have continuing 
severe and persistent problems with social functioning. We aimed to assess the efficacy of 
early intervention services augmented with social recovery therapy in patients with first-
episode psychosis. The primary hypothesis was that social recovery therapy plus early 
intervention services would lead to improvements in social recovery. 
 
Methods:  We did this single-blind, phase 2, randomised controlled trial (SUPEREDEN3) at 
four  specialist early intervention services in the UK. We included participants who were 
aged 16–35 years, had non-affective psychosis, had been clients of early intervention 
services for 12–30 months, and had persistent and severe social disability, defined as 
engagement in less than 30 h per week of structured activity. Participants were randomly 
assigned (1:1), via computer-generated randomisation with permuted blocks (sizes of four 
to six), to receive social recovery therapy plus early intervention services or early 
intervention services alone. Randomisation was stratified by sex and recruitment centre 
(Norfolk, Birmingham, Lancashire, and Sussex). By necessity, participants were not masked 
to group allocation, but allocation was concealed from outcome assessors. The primary 
outcome was time spent in structured activity at 9 months, as measured by the Time Use 
Survey. Analysis was by intention to treat.  
 
Findings: Between Oct 1, 2012, and June 20, 2014, we randomly assigned 155 participants 
to receive social recovery therapy plus early intervention services (n=76) or early 
intervention services alone (n=79); the intention-to-treat population comprised 154 
patients. At 9 months, 143 (93%) participants had data for the primary outcome. Social 
recovery therapy plus early intervention services was associated with an increase in 
structured activity of 8·1 h (95% CI 2·5–13·6; p=0·0050) compared with early intervention 
services alone. No adverse events were deemed attributable to study therapy. 
Interpretation: The findings show a clinically important benefit of enhanced social recovery 
for the SRT plus EIS group on the primary outcome of structured activity. 
Funding: National Institute for Health Research (NIHR). 
BACKGROUND 
The provision of Early Intervention Services (EIS) for first episode psychosis (FEP) has 
resulted in considerable gains in social outcome in comparison to traditional more generic 
mental health services for this group1-3. Estimates of the rate of social recovery outcomes 
before the provision of EIS were as low as 15% making either a partial or full social recovery 
at two years4. EIS provide a range of interventions that aim to facilitate social recovery, 
including recovery oriented intensive outreach case management5,6. The provision of EIS has 
improved the rate of social recovery to between 40% and 60%4,7. 
Nevertheless, a significant proportion of individuals have continuing severe and persistent 
problems with social functioning, even after 12 months of specialist EIS provision8. Cases 
which show poor response to EIS often represent a subgroup who, although presenting with 
first episode psychosis, often have chronic severe and complex mental health and social 
functioning problems that date back premorbidly to childhood predating the onset of 
psychosis by many years8. The types of problems associated with social recovery in FEP are 
complex and include: poor engagement with service providers; loss of role and social 
contacts; perceived stigma and shame; anxiety and depression; and treatment resistant 
psychotic symptoms9. These persistent difficulties often result in lifelong patterns of social 
withdrawal10.  Addressing these issues at an early stage is key as we have known for 
decades that the presence of persistent early social decline is associated with a poor long 
term course in schizophrenia11. In addition to the personal consequences of functional 
disability, there are large financial implications for society, with much of the cost of 
psychosis resulting from lost productivity12. 
There is a need for new interventions targeting functional and social recovery in FEP. Whilst 
conventional Cognitive Behavioural Therapy (CBT) for psychosis has some evidence of 
effectiveness on social disability as a secondary outcome even where the primary focus has 
been on reducing positive symptoms of psychosis13.  More specific adaptations of CBT for 
psychosis targeting negative symptoms and social recovery have shown promise14-16.  
Functional interventions such as Individual Placement and Support (IPS) have been found to 
be effective in helping individuals to return to paid employment17. However, IPS is most 
successful with individuals who are motivated to engage and wish to work and may be less 
effective for individuals who have poor engagement, who are ambivalent about change, and 
who continue to experience comorbid difficulties17. Intervention needs to target a wider 
construct of social recovery than work alone.  This includes education and voluntary work, 
as well as household activity and childcare, which are productive economic activities. Pro-
social activity with peers is also key in ensuring young people achieve development 
milestones and continue to thrive at a key stage in life. Such principles are consistent with 
the user oriented goals identified by the recovery movement18,19.  
We have developed an intervention which focuses on social recovery. The rationale behind 
Social Recovery Therapy (SRT)9 is that 'in vivo' multi-systemic assertive outreach and case 
management are necessary to encourage more socially withdrawn individuals back into 
social environments, whilst the techniques of CBT are necessary to promote engagement 
and overcome the symptoms that impede this. It is the intensive and novel combination of 
these elements of therapy that provides the possibility of making meaningful changes to the 
lives of very withdrawn and difficult to engage young people who have not previously 
responded to standard EIS provision. 
Preliminary evidence for the efficacy of SRT derives from the ISREP MRC trial platform study 
which suggested that the intervention can improve social recovery in individuals in the early 
stages of psychosis and is cost-effective14,20. In the ISREP trial, unemployed adults with up to 
8 year histories of non-affective psychosis showed significant improvements in structured 
activity, symptoms, hopelessness and rates of employment after receiving 9 months of SRT. 
Whilst the findings of the ISREP study are promising, targeting social disability at an even 
earlier stage may improve outcomes. 
The objective of the present study is to evaluate the efficacy of adding SRT to EIS with the 
aim of achieving a step-change in early social recovery in young people who have severe and 
persistent social disability despite receiving EIS services for over a year after their first 
episode of psychosis. The primary hypothesis was that augmenting EIS with SRT would lead 
to improvements in time spent in structured activity at 9 months. The secondary hypotheses 
were that the effects on activity would persist at 15 months and that there would be 
benefits on general psychopathology and negative symptoms.  
 
 
METHODS 
Study Design 
The study was a single blind, phase 2 trial, comparing the augmentation of EIS with SRT with 
provision of EIS alone. The study was conducted in 4 well established Early Intervention 
Services in the UK. The intervention lasted for 9 months with assessments at baseline, end 
of therapy (9 months); and 15 months (6 months after the end of therapy). The primary 
outcome was hours per week engaged in structured activity post-intervention at 9 months, 
assessed using the Time Use Survey. Ethical approval for the study was granted by the 
National Research Ethics Service (NRES) Committee, in the Black Country, West Midlands 
(Ref: 12/WM/0097). 
Participants 
Study inclusion criteria were: (1) patients with non-affective psychosis; (2) clients of EIS in 
Birmingham, Lancashire, Norfolk and Sussex (in the UK criteria for entry into EIS is 
operationally defined as having psychotic symptoms at or above PANSS 4); (3) showing a 
low level of structured activity after at least one year of treatment from EIS (defined as 30 
hours or less per week on the Time Use Survey); (4) clients had been with EIS between 1-2 
years; and (5) both males and females aged between 16-35 years Participants were 
excluded if they: (1) were part of the original National EDEN cohort (2); did not speak 
adequate English to engage in the intervention; and (3) were considered too unwell to 
engage with the intervention. Potential participants were approached by their care co-
ordinator and asked if they were willing to discuss the trial with a research assistant (RA). 
Information about the trial was shared verbally and via the participant information sheet. 
Written informed consent for screening and full participation in the study was taken by the 
RA. Participants were made aware that they could withdraw at any time, without any 
consequences for their treatment.  
Randomisation and masking 
Participants were randomly assigned to SRT plus EIS or EIS alone in a 1:1 ratio using an 
automated, concealed, computer generated allocation sequence generated by Norwich 
Clinical Trials Unit independently of the trial team, and were stratified by gender and 
recruitment centre (Norfolk, Birmingham, Lancashire, Sussex).  The randomisation sequence 
used permuted blocks with randomly varying block size.   
Email notification of the allocation was sent automatically to therapists and the trial 
manager. An email notification confirming that the participant had been randomly assigned 
(with no information about group allocation) was sent to the RA, thus keeping them masked 
to group assignment. Therapists were also required to consider potential breaches in 
masking; and participants were reminded by assessors not to disclose treatment allocation. 
When masking was broken, another rater who was masked to group assignment assessed 
the participant at all subsequent timepoints.  
Interventions 
Early Intervention Service (EIS) 
All participants received EIS provision from specialist teams. The teams in Birmingham, 
Lancashire, Norfolk and Sussex are all recognised centres of excellence for delivery of EIS. 
They all demonstrate high fidelity to the EIS model, indicating services which had the 
availability to deliver a comprehensive range of interventions21.  These interventions include 
intensive and assertive recovery oriented case management; supported employment; peer 
support; group interventions; family work and CBT for psychosis as well as psychiatric 
medications and medical and psychiatric monitoring.  All participants had an EIS case 
manager who provided oversight of their care and remained in contact with the participant 
throughout the trial.  
Social Recovery Therapy (SRT)  
In the treatment condition, care from EIS was augmented by SRT delivered by a therapist 
who was trained and supervised by the trial team. All therapists were supervised and 
accredited CBT therapists with experience in the participating EIS services.  SRT practice in 
this trial was designed and supervised to ensure it was carried out in partnership with the 
EIS care. 
The specific therapeutic procedures used in SRT were developed by DF, PF and JH. They 
draw from our experience in the MRC ISREP trial platform14 and details are provided in our 
published manual9.  In summary SRT is delivered in three stages as follows:  
Stage 1: Engaging and developing a Formulation. This consists of establishing a working 
therapeutic relationship to facilitate engagement and identify a problem list. Alongside this 
is a detailed assessment of personal motivation and premorbid hopes, expectations and 
goals which may have changed or altered with respect to the impact of illness. Specific 
behavioural assessment is carried out in vivo to assess how symptoms impact on activity. 
Links are identified between personally meaningful values and goals and achievable day-to-
day activity targets. 
Stage 2: Preparing for new activities. The client and therapist work together to identify 
pathways to meaningful new activities. This includes referral to relevant vocational 
agencies, education providers, and community providers of social or sports activities. 
Cognitive work at this stage involves promoting a sense of agency and addressing 
hopelessness, feelings of stigma, and negative beliefs about self and others.  Behavioural 
experiments start focussing on managing symptoms while engaging in activity. 
Stage 3: Engaging in new activities. This involves the active promotion of social activity using 
behavioural experiments, and fostering feelings of mastery and agency. The behavioural 
experiments are progressively shaped to address specific problems presented by individuals. 
Therapists adopt an assertive outreach style of contact, most frequently visiting people at 
home, or in community settings. Therapists are also encouraged to work systemically with 
family members, employers and educational providers to discuss and overcome potential 
problems which may represent blockages to social recovery.  
Therapy competence and fidelity to SRT model 
All trial therapists had formal training in CBT. In addition, they received specialist training in 
the SRT approach via workshops and regular supervision sessions from the trial therapy 
team including DF, PF and JH. The revised Cognitive Therapy Rating Scale22 was used to 
ensure therapist competence. All therapists were required to score above 36 from tape 
rated sessions and an average of above 3 on each item. Adherence to the SRT model was 
also assessed using a specific checklist.  This method used a combination of independent 
expert rating of case notes and therapist ratings of individual sessions to assess techniques 
applied in individual sessions. A sufficient dose of therapy was defined as at least 6 sessions, 
including the presence of an assessment and formulation phase and active behavioural 
experiments occurring in at least two independent sessions.  
Outcomes 
Study assessments took place at baseline, 9 months (post-intervention), and 15 months (6 
months post-intervention). RAs visited participants at home to undertake assessments and 
used flexible strategies to maintain engagement with participants such as re-arranging 
missed appointments to maintain participation. Inter-rater reliability on outcome measures 
was ensured via regular training sessions for RAs and fortnightly telephone supervision 
meetings to discuss assessment queries. Data were collected according to the original 
funded protocol as submitted to and approved by the National Research Ethics Service 
(NRES) Committee, in the Black Country, West Midlands (Ref: 12/WM/0097). A briefer 
protocol summarising only the primary and secondary outcomes was published as the 
registered trial protocol. We report all data collected in this paper.  
The trial was conducted in accordance with Good Clinical Practice (GCP) and the data 
analysed according to a Statistical Analysis Plan (SAP) developed prior to the unblinding of 
data, dated 06/11/2015. The SAP differed from the original ISCTRN protocol in that it was 
more specific in identifying the analysis of primary outcome as time use at 9 months, and 
also identified a range of secondary outcomes. These changes to the analysis plan took 
place after the ISCTRN protocol was published in June 2012 following further 
methodological review and particularly taking into account considerations of multiplicity for 
the analysis of primary outcome, in particular avoiding type 1 error through multiplicity23. 
These changes were discussed with and approved by the Trial Steering Committee and were 
recorded in the trial documentation. 
 
Primary Outcome 
The primary outcome measure was Structured Activity measured by the Time Use Survey 
(TUS) as adapted for work in this client group24 assessed at 9 months. The TUS is a semi-
structured interview which enquires about time spent over the last month in work, 
education, voluntary work, leisure, sports, housework/chores, and childcare. Time spent on 
each of the activities is calculated in terms of the average number of hours per week. The 
activities are summed to create two scores: ‘Constructive Economic Activity’ (work, 
education, voluntary work, housework/chores, and childcare) and ‘Structured Activity’ 
(Constructive Economic Activity plus leisure and sports activities). The TUS has been 
adapted from a version developed by the UK Office for National Statistics25 enabling activity 
levels to be directly compared with age-matched non-clinical peers. On average, a non-
clinical group aged between 16-36 years engage in 63.49 hours of structured activity per 
week, and activity levels below 30 hours are indicative of poor social functioning24. The 
intra-class correlation coefficient (ICC) for inter-rater reliability on the TUS was .99. The TUS 
was also administered at 15 months. Structured Activity and Constructive Economic Activity 
at 15 months were recorded to explore the tenacity of the treatment effect. However, the 
SAP is clear that the primary outcome for the study was the TUS at 9 months. 
Secondary Outcomes 
The Positive and Negative Syndrome Scale (PANSS)26 was used to assess general 
psychopathology and negative symptoms as secondary outcomes. Other secondary 
outcomes at 9 and 15 months included the Schedule for the Assessment of Negative 
Symptoms (SANS)27; the Social Interaction Anxiety Scale (SIAS)28; the Beck Depression 
Inventory-II (BDI-II)29; the Beck Hopelessness Scale (BHS)30; the Meaning in Life 
Questionnaire (MLQ)31; and the Adult Trait Hope Scale (ATHS)32. 
Health Economic Outcomes 
The Client Service Receipt Inventory (CSRI)33 and the EuroQol-5D34 were administered in 
order to conduct a health economic evaluation of the intervention. These were included in 
the trial protocol as secondary outcomes but are not reported here as they are the subject 
of another paper.  
Mediators 
A range of other scales were included to assess potential mediation of outcome. The Quality 
of Life Scale (QLS)35 and the Role and Social Global Functioning Scales (RSGF)36 were 
included in the original trial protocol as secondary outcomes but are not reported here as 
are the subject of another paper investigating mediation effects. Other mediator variables 
included the Schizotypal Symptoms Inventory (SSI)37; the Brief Core Schema Scales (BCSS)38; 
and a range of neuropsychological variables. Data from these variables are also the subject 
of another paper investigating mediation effects.  
Safety and Adverse Events 
Serious and adverse events were recorded over the course of the trial using standard 
operating procedures and reported to the NHS research ethics committee.  
Statistical Analysis 
Analysis of the primary outcome was by intention to treat. The planned recruitment to the 
trial was based on a sample size of 150 individuals. A consensus group of clinicians and 
service users had conservatively estimated the minimum clinically significant gain on the 
primary outcome as 4 hours on the Time Use Survey. With a standard deviation of 8 hours 
and a minimum clinically important difference of 4 hours, we had 90% power to detect a 
difference of 4 hours to be significant at the conventional alpha level (two sided) of 5% with 
150 subjects randomised 1:1, recruited across 4 sites. The trial as designed had 80% power 
to find the same effect with 120 evaluable patients. 
The primary outcome was assessed using generalised mixed models, with an identity link 
and Gaussian/mixed error.  Each subject contributed two observations; one at baseline and 
one at 9 months. The model included indicators for whether the observation is baseline or 9 
months, and whether or not the subject was randomised in that period to receive the active 
intervention or control.  In addition, all models included the stratification variables as 
patient level explanatory factors (gender and recruitment centre).  Observations were linked 
using random intercept terms within a patient.  Denominator degrees of freedom were 
derived from the number of patients.  Supportive analyses were conducted using the 
separate components of the primary outcome.  In addition, the primary outcome was 
analysed using residual (r side) random effects instead of generalised (g side) random 
effects.  A further supportive analysis was undertaken including baseline score as a patient 
level explanatory variable. 
The principal analysis was planned on all available subjects by intention to treat, without 
imputation of missing values.  Missing data were assumed to be missing not at random.  
Supportive analyses addressed missing data patterns by modelling jointly the continuous 
outcome score (with Gaussian error) and observed loss to follow up (with Bernoulli error), 
to describe the joint probability of the observed outcome.   The joint (multivariate) models 
require the assumption that those who provide missing data are, on average, poorer 
performers than those who did not drop out.  This defensible assumption simply implies 
that loss to follow up is a measure of poor performance on the scale of interest. All analyses 
were conducted in SAS software, Version 9.4 (SAS Institute Inc, Carey NC, USA). 
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication. 
RESULTS 
Participants were recruited over 20 months between 1st October 2012 and 30th June 2014. A 
CONSORT diagram showing study design and participant flow through the study up to 
randomisation and treatment allocation is shown in Figure 1. The final sample size was 154 
(39 Birmingham, 53 Lancashire, 47 Norfolk and 16 Sussex) with 75 randomised to EIS plus 
SRCBT and 79 randomised to EIS alone.   The independent data monitoring and ethics 
committee monitored all serious and adverse events. The committee found no serious or 
adverse events attributable to the therapy. 
Table 1 provides baseline demographic characteristics of the sample by treatment and 
control conditions. The sample were predominantly male, single and of White 
British/Irish/Other ethnicity. Length of illness and duration of untreated psychosis were 
variable but, as per the study inclusion criteria, all participants had been engaged with EIS 
for between 12 and 30 months. Table 2 provides means and medians of baseline, primary 
and secondary outcomes by treatment and control conditions and Table 3 provides results 
of the prespecified statistical analysis plan. Tables 4 and 5 provide data for mediator 
variables. Of note is the severity of social disability, psychotic symptomatology, anxiety and 
depression present in the sample at baseline.  
Participants allocated to the EI plus SRCBT condition received a mean of 16.49 sessions of 
SRT (SD = 8.39; range 0 to 37). Competence in cognitive therapy as assessed by the CTS-R 
was excellent. Of the random selection of therapy tapes rated independently, 27/30 (90%) 
scored higher than the cut off based on the therapy protocol. Adherence ratings on the 
SRCBT checklist indicated that 61 (81.3%) participants received a sufficient dose of SRT.  
Seven participants dropped out and did not have ratings available, and 7 did not receive a 
sufficient dose.  
As can be seen in Tables 2 and 3, for the primary outcome at 9 months, 143 participants 
(93%) provided data on the primary outcome (7% missing data overall, with 2.67% in the 
SRT plus EIS group and 11.39% in EIS alone). This was regarded as satisfactory for an 
intention to treat (ITT) analysis. The primary ITT analysis indicated that the intervention (SRT 
plus EIS) was associated with a large and clinically important increase in structured activity 
8.1 hours (95% CI 2.5 to 13.7; p = 0.0050) compared with EIS alone at 9 months. The 
supportive analysis using a repeated measure analysis (residual random effect) provided a 
similar estimate (8.8 hours; 95% CI 1.3 to 16.3). The supportive analysis utilising baseline 
value as a patient level explanatory variable provided an estimate of 8.9 hours (95% CI 1.4 
to 16.5). 
For secondary outcomes, despite considerable effort to retain participants, the missing data 
were greater, particularly for face-to-face assessments. For time use at 15 months there 
were 17% missing data overall (9% for SRT plus EIS and 24% for EIS alone). For the PANSS 
missing data were 20% total (12 % SRT vs 28% EIS) at 9 months and 35% total (24% SRT vs 
41% EIS) at 15 months. The pattern of missing data was clearly biased, with greater missing 
data in the EIS alone condition, and was thus regarded as Missing Not at Random.  
A completer case analysis was first used for the analysis of secondary outcomes, in 
accordance with the protocol and the Statistical Analysis Plan. In addition, a joint modelling 
(multivariate) strategy was applied to account for missing data. This approach assumes that 
loss to follow up is associated with poor performance on the scale of interest.  The analysis 
of secondary outcomes by both completer analysis and the results of the joint models, 
which provide p values alone, are described in Table 3.   
Analysis of treatment effects for Time Use at 15 months and other secondary outcomes  
using completer analysis showed no systematic differences between experimental 
conditions. However the results of the joint models provided supportive evidence that, 
conditional on the assumption that loss to follow up is associated with a poorer score on 
time use, the observed results are consistent with systematic differences in several 
secondary outcomes. These include: structured (p=0.037) and constructive economic 
(p=0.046) time use at 15 months;PANSS negative symptoms (p=0.032) and general 
psychopathology (p=0.043) at 9 months; SIAS at 9 months (p=0.016); BHS at 9 months 
(p=0.020) and 15 months (p=0.022); Trait Hope at 15 months (p=0.0060); and MLQ at 15 
months (p=0.043).  
DISCUSSION 
The primary aim of this study was to establish the presence of a treatment effect in a 
subgroup of patients we know to be hard to treat, who tend not to engage and have 
complex problems, and are the poorest outcome EI subgroup for whom there is no existing 
effective treatment.  The study was powered on an effect on the primary outcome at 9 
months. The result at 9 months for the primary outcome is clear and definitive. The 
participants who received SRT plus EIS achieved an improvement of greater than 8 hours 
per week in their level of structured activity compared to those receiving EIS alone. Hence, 
those receiving SRT in combination with EIS provision made a large, significant and clinically 
important gain in activity compared to those receiving EIS alone after 9 months of 
intervention. This is the first study to demonstrate a significant improvement in functioning 
in this already highly disabled group. The size of the effect is twice that which consensus 
groups of users and clinicians had identified as the minimum clinically important difference, 
and it represents an amount of activity equivalent to a working day.  The evidence from the 
primary analysis is therefore clear that SRT may have a clinically important effect in 
promoting earlier social recovery in comparison to EIS provision alone. 
The key issue for secondary outcomes was whether or not this effect persists at 15 months. 
The main problem was a high rate of missing data at that point. This meant all analyses of 
secondary outcomes lacked power and were difficult to interpret. This population is 
incredibly challenging to keep in follow up and the excellent response rate for the primary 
outcome is a tribute to the efforts of the field researchers involved in the study.  
Missingness is clearly related to the outcomes of interest as availability for assessments by 
participants is related to social engagement, and social recovery therapy specifically aims to 
increase social engagement.  At all assessment points many more participants were 
available for follow up assessments in the SRT group than in the EIS alone group. Loss to 
follow up at 15 months for TUS is over twice the rate in the control condition as in the 
experimental group (9.3% vs 24.1%).   This in itself may imply an effect of the intervention 
on engagement which most clinicians would regard as useful and worthy of examination in a 
future study. However, the pattern of differential missingness represents a challenge to 
interpreting the effect at 15 months as it may formally be regarded as Missing not at 
random. Completor analysis suggests that the means the outcomes at 15 months are similar 
between the groups but this may be biased if it is the worst outcome cases who dropped 
out. The joint models analysed simultaneously the outcome of interest and the binomial of 
missing values for that outcome and was intended to provide a least biased assessment 
appropriate to the data being Missing not at random.  Modelling the two values 
simultaneously in the multivariate model accounts for bias and provides a more 
encouraging overall p value for the difference between the two experimental conditions p = 
0.037. Although reliant on the assumption that drop out equals worse outcome on the scale 
of interest, the joint modelling analyses provide encouragement that at least some of the 
effect of the experimental treatment on time use may remain at 15 months, albeit with a 
level of attenuation when compared with the similarly derived 9 month values.  A limitation 
of the joint modelling approach is it provides only a p value for the combined 
pseudolikelihoods of the outcome and drop out, and cannot provide an updated estimate or 
confidence interval for the treatment effect.   
A further question for secondary outcomes was the effect on negative symptoms and 
general psychopathology as assessed by PANSS.  Again the presence of large degree of 
missing data does not allow a firm conclusion about these outcomes and the completor 
analysis suggests there is no effect, but the joint modelling which attempts to account for 
missing data suggests an impact on these outcomes at 9 months.  
Of the 206 individuals identified as meeting inclusion criteria, a large proportion (75%) 
consented and were randomised into the study. This was the result of intensive and 
assertive recruitment procedures. The RAs worked in an assertive outreach manner, visiting 
participants at home and engaging them into the study. The result was the recruitment of a 
group with very severe and stable social disability. The total time spent in activity by the 
group recruited for the study was less than 12 hours per week, compared to over 60 hours 
per week in an age-matched non-clinical sample24. This was a group of young people with 
extreme social withdrawal who also had a wide range of other comorbid and complex 
comorbidities, including high levels of treatment resistant and residual positive psychotic 
symptoms, negative symptoms, anxiety and depression, as well as the presence of current 
hopelessness and a lack of hope for the future.  
The present study extends the previous ISREP trial platform study of SRT which compared 
SRT to treatment as usual in finding a benefit at 9 months and at 15 months and 2 year 
follow up, and with associated gains in secondary outcomes and cost effectiveness14,20. The 
present study represents a more rigorous test as in this study the comparator intervention 
was a highly active treatment, EIS provision. Treatment as usual in the present study 
consisted of high quality EIS provision in sites with good fidelity to the EIS model, as 
recommended by NICE guidelines for psychosis and schizophrenia39. Improvements were 
observed in both treatment conditions but with differential improvement in the SRT arm.  
A strength of this study was good internal and external validity for the trial on the primary 
outcome. The study was conducted with a high degree of rigour with all researchers and 
therapists involved in the study receiving regular supervision and with routine checks on 
inter-rater reliability and adherence to the therapy model.   
A limitation of the study was that it was compromised by the level and pattern of missing 
data in the secondary outcomes, albeit one that was addressed using joint modelling. The 
characteristics of the target group in this study being by definition a difficult to engage and 
extremely withdrawn sample represent a challenge to researchers, especially where follow 
up assessments are reliant on face to face assessments. Potentially future studies in this 
area might maximise rate of follow up by focussing on hard proxy variables of engagement 
in services which may be derived from records rather than face to face assessments 
especially as engagement is of itself an important outcome in this population. A further 
limitation of this study was that many of the secondary outcomes have wide confidence 
intervals (an indication of low statistical power) suggesting low precision or uncertainty in 
the estimation of treatment effects. Further the study was by necessity single blind, and 
thus may be affected by the experience of the subject in receiving therapy. 
The target group for this study was a particularly severe group of young people with first 
episode psychosis who we know are likely to have poor long term outcomes. This study 
provides encouragement for EIS practitioners to focus on this subgroup who are often 
neglected and adopt these type of practices. This is the first study to show benefits for this 
group. The effect size after treatment is clearly of clinical benefit, especially given the 
extreme social withdrawal present at baseline. Furthermore, the very fact of differential 
drop out with many more receiving treatment being available to follow up than in the 
control implies benefits on maintaining engagement in the treatment group which may be 
important to assess as an outcome in and of itself in future work.  The degree to which the 
treatment results in persistence of gains and longer term effects deserves further study. 
Joint modelling aimed to account for the bias associated with the differential pattern of 
missingness in the analysis and suggests the potential for persistence of effects over the 
longer term, but as this was a supplementary analysis, persistence of gains cannot be 
established. A larger more definitive trial is required to examine more clearly effects over 
the longer term. The extent to which interventions of this type may be enhanced by ‘top up’ 
therapy or greater numbers of sessions over a longer duration may be worthy of further 
scrutiny given evidence from similar studies in adults with more established schizophrenia16. 
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Figure 1. Trial Profile 
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Table 1  
Baseline Demographic Information for the Intent to Treat Population  
Item Standard Care  
n=79 
SRCBT + Standard 
Care n=75 
Male n (%) 60 (75.95%) 56 (74.67%) 
Age, median (IQR) 24.15  
(22.17, 27.79) 
24.84  
(20.73, 29.04) 
Length of illness in months, median (IQR) 26 (20, 38) 23.5 (17, 33) 
Duration of Untreated Psychosis in days, 
median (IQR) 
66 (20, 240.75) 73 (13, 316) 
Premorbid Adjustment, mean (SD) 
Early Adolescence 
Late Adolescence 
 
0.34 (0.15) 
0.36 (0.17) 
 
0.33 (0.20) 
0.34 (0.17) 
Years in Schooling 12 (11, 12) 12 (11, 13) 
Ethnic Group   
 British 58 (73.42%) 55 (73.33%) 
 Irish 2 (2.53%) 1 (1.33%) 
 Any other White background 1 (1.27%) 2 (2.67%) 
 White and Black Caribbean 2 (2.53%) 0 (0%) 
 White and Black African 0 (0%) 1 (1.33%) 
 White and Asian 0 (0%) 2 (2.67%) 
 Any other mixed background 0 (0%) 1 (1.33%) 
 Indian 1 (1.27%) 0 (0%) 
 Pakistani 6 (7.59%) 7 (9.33%) 
 Bangladeshi 1 (1.27%) 1 (1.33%) 
 Any other Asian background 1 (1.27%) 1 (1.33%) 
 Caribbean 4 (5.06%) 0 (0%) 
 African 2 (2.53%) 1 (1.33%) 
 Any other Black background 0 (0%) 1 (1.33%) 
 Any other ethnic group 1 (1.27%) 2 (2.67%) 
Mother Tongue   
 English language 75 (94.94%) 69 (92.0%) 
 Other language (but having good   
knowledge of English language) 
4 (5.06%) 6 (8.0%) 
Marital Status 
Single 
Cohabiting 
Married 
Divorced 
 
69 (87.34%) 
5 (6.33%) 
3 (3.80%) 
2 (2.53%) 
 
67 (89.33%) 
4 (5.33%) 
4 (5.33%) 
0 (0%) 
 
Table 2        
Primary and secondary outcomes at baseline, 9 months and 15 months  
 
 Baseline 9 months 15 months 
 SRT +EIS EIS  
alone 
SRT +EIS EIS  
alone 
SRT + EIS EIS  
alone 
Primary Outcomes       
Structured activity 11(7.5) 
n=75 
12(8.6) 
n=79 
26.6(24.2) 
n=73 
18(20) 
n=70 
23(19) 
n=68 
22.5(23.3) 
n=60 
Constructive economic 
activity 
7.5(6.1) 
n=75 
7.9(7.5) 
n=79 
20.1(22) 
n=73 
14.1(20) 
n=70 
16.4(17) 
n=68 
16.5(23.3) 
n=60 
Secondary Outcomes       
PANSS* 62(27) 
n=75 
65(27) 
n=79 
54(34)  
n=66 
58(18) 
n=57 
48(28) 
n=57 
56(25)  
n=46 
SANS* 23(21) 
n=74 
27(18) 
n=78 
19(22)  
n=64 
18(23) 
n=57 
20(26) 
n=57 
21(21)  
n=47 
BDI* 18(19) 
n=73 
19(21) 
n=75 
12(21)  
n=62 
16(16) 
n=55 
9(18)  
n=55 
8(16)  
n=43 
SIAS* 40(20) 40(22) 37(28) 37(20) 36(27) 34(30)  
 Note. Data are mean and SD unless indicated by * in which case median and interquartile ranges. Some scales 
have missing data and numbers are provided to indicate sample without complete data. PANSS= Positive and 
Negative Symptom Scales; SANS=Scale for Assessment of Negative Symptom; BDI= Beck Depression Inventory; 
SIAS- Social Interaction an Anxiety Scales; BHS=Beck Hopelessness Scales; ATHS= Adult Trait Hope Scale; MLQ= 
Meaning in Life Questionnaire 
 
 
 
 n=69 n=72 n=64 n=53 n=56 n=43 
BHS* 8(8)  
n=67 
9(7)  
n=67 
5(7)  
n=59 
7(9)  
n=56 
4(6)  
n=56 
5(8)  
n= 42 
ATHS Sense of agency* 15(10) 
n=68 
18(11) 
n=67 
19(11)  
n=54 
17(12) 
n=46 
21(7)  
n=53 
19(10)  
n=40 
ATHS Optimism* 20(8) 
n=68 
19(11) 
n=67 
21(7)  
n=54 
20(8)  
n=46 
22(7)  
n=53 
20(6)  
n=40 
Meaning in life* 39(11) 
n=67 
42(14) 
n=68 
40(13)  
n=56 
42(12) 
n=46 
40(12) 
n=52 
41(18)  
n= 40 
Table 3 
Results of prespecified outcome analysis and joint models for primary and secondary outcomes 
Analysis Estimate Lower 
95% CI 
Upper 95% CI P Missing 
(intervention) 
N = 75 r(%) 
Missing 
(Control) n = 79 
(r(%) 
P value Joint 
Model 
Primary Outcomes        
Structured Activity at 9 
months 8.080 2.502 13.657 0.0050 
 
2 (2.7%) 
 
9 (11.4%) 
 
0.011 
Constructive Economic 
Activity at 9 months 5.859 0.790 10.928 0.024 
 
2 (2.7%) 
 
9 (11.4%) 
 
0.034 
Secondary Outcomes        
Structured Activity at 15 
months 0.054 -5.154 5.262 0.98 
 
7 (9.3%) 
 
19 (24.1%) 
 
0.037 
Constructive Economic 
Activity at 15 months -0.506 -5.048 4.036 0.83 
 
7 (9.3%) 
 
19 (24.1%) 
 
0.046 
Positive PANSS 9 months 0.306 -1.228 1.840 0.69 9 (12.0%) 22 (27.9%) 0.068 
Negative PANSS 9 months -1.020 -2.662 0.622 0.22 9 (12.0%) 22 (27.9%) 0.032 
General PANSS 9 months -1.014 -3.514 1.486 0.42 9 (12.0%) 22 (27.9%) 0.043 
Positive PANSS 15 months 1.219 -0.632 3.071 0.19 18 (24.0%) 32 (40.5%) 0.071 
Negative PANSS 15 months -0.629 -2.411 1.152 0.49 18 (24.0%) 32 (40.5%) 0.073 
General PANSS 15 months -0.084 -3.031 2.862 0.96 18 (24.0%) 33 (41.8%) 0.081 
SANS Total at 9 months 9.713 -14.568 33.994 0.43 11 (14.7%) 20 (25.3%) 0.17 
SANS Total at 15 months 16.798 -10.553 44.147 0.23 18 (24.0%) 32 (40.5%) 0.035 
BDI at 9 months -1.567 -4.840 1.706 0.35 13 (17.3%) 24 (30.4%) 0.10 
BDI at 15 months 0.748 -3.261 4.757 0.71 20 (26.7%) 36 (45.6%) 0.067  
SIAS at 9 months -2.559 -6.964 1.846 0.25 11 (14.7%) 26 (32.9%) 0.016 
SIAS at 15 months 1.490 -4.132 7.111 0.60 19 (25.3%) 36 (45.6%) 0.10 
BHS at 9 months -1.464 -3.282 0.354 0.11 16 (21.3%) 33 (41.8%) 0.020 
BHS at 15 months -1.451 -3.257 0.355 0.11 19 (25.3%) 37 (46.8%) 0.022 
ATHS total score 9 months 2.214 -1.504 5.931 0.24 21 (28.0%) 33 (41.8%) 0.15 
ATHS total score 15 months 3.860 -0.266 7.987 0.066 22 (29.3%) 39 (49.4%) 0.0060 
Note. PANSS= Positive and Negative Symptom Scales; SANS=Scale for Assessment of Negative Symptom; BDI= Beck Depression Inventory; SIAS- Social Interaction an 
Anxiety Scales; BHS=Beck Hopelessness Scales; ATHS= Adult Trait Hope Scale; MLQ= Meaning in Life Questionnaire 
 
MLQ total score 9 months 2.193 -1.496 5.883 0.24 19 (25.3%) 33 (41.8%) 0.12 
MLQ total score 15 months 0.782 -3.196 4.759 0.70 23 (30.7%) 39 (49.4%) 0.043 
